CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Series A Preferred Stock Preferred Stock	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit	Total
Balance Beginning at Dec. 31, 2020	$ 4,469	$ 37	$ 444,622		$ (311,929)	$ 137,199
Balance Beginning (in shares) at Dec. 31, 2020	4,753	36,578,460		7,307
Increase (Decrease) in Stockholders' Equity (Deficit)
Stock-based compensation expense			13,867			13,867
Exercise of stock options			1,199			1,199
Exercise of stock options (in shares)		176,194
Financing costs			(3)			(3)
Conversion of convertible preferred stock into common	$ (167)		167
Conversion of convertible preferred stock into common (in shares)	(178)	35,600
Net loss					(98,776)	(98,776)
Balance Ending at Dec. 31, 2021	$ 4,302	$ 37	459,852		(410,705)	53,486
Balance Ending (in shares) at Dec. 31, 2021	4,575	36,790,254		7,307
Increase (Decrease) in Stockholders' Equity (Deficit)
Stock-based compensation expense			14,890			14,890
Issuance of common stock and pre-funded warrants		$ 13	64,464			64,477
Issuance of common stock and pre-funded warrants (in shares)		12,421,053
Exercise of stock options			1,794			1,794
Exercise of stock options (in shares)		238,312
Issuance of restricted stock (in shares)		14,893
Issuance of stock related to IP license agreement with Ovid			1,169			1,169
Issuance of stock related to IP license agreement with Ovid (in shares)		123,255
Conversion of convertible preferred stock into common	$ (259)		259
Conversion of convertible preferred stock into common (in shares)	(275)	55,000
Net loss					(19,816)	(19,816)
Balance Ending at Dec. 31, 2022	$ 4,043	$ 50	$ 542,428		$ (430,521)	$ 116,000
Balance Ending (in shares) at Dec. 31, 2022	4,300	49,642,767		7,307